^
BIOMARKER:
BRAF mutation
i
Other names: BRAF, B-raf proto-oncogene, B-raf proto-oncogene, Serine/threonine kinase, V-Raf murine sarcoma viral oncogene homolog B, Serine/threonine-protein kinase B-Raf, Proto-oncogene B-Raf, BRAF1, RAFB1, B-raf proto-oncogene Serine/threonine-protein kinase, Murine sarcoma viral (V-Raf) oncogene homolog B1, B-raf serine/threonine-protein, 94 KDa B-raf protein, B-RAF1
Entrez ID:
Related biomarkers:
BRAF mutation
NSCLC
PD-L1 inhibitor
Sensitive
:
C3
Eur J Cancer - 3wk
BRAF mutation
NSCLC
PD1 inhibitor
Sensitive
:
C3
Eur J Cancer - 3wk
BRAF mutation
Melanoma
dabrafenib + granisetron intravenous
Sensitive
:
A2
BRAF mutation
CRC
ramucirumab
Sensitive
:
B
BRAF mutation
CRC
ziv-aflibercept IV
Sensitive
:
B
BRAF mutation
CRC
bevacizumab
Sensitive
:
B
BRAF mutation
CRC
cetuximab
Resistant
:
B
BRAF mutation
CRC
regorafenib
Sensitive
:
B
BRAF mutation
Melanoma
nivolumab + ipilimumab
Sensitive
:
B
BRAF mutation
CRC
FOLFIRI + cetuximab
Sensitive
:
B
BRAF mutation
AML
gilteritinib
Resistant
:
B
BRAF mutation
Melanoma
PD-L1 inhibitor
Sensitive
:
B
BRAF mutation
Melanoma
ipilimumab
Sensitive
:
B
BRAF mutation
CRC
panitumumab
Sensitive
:
C2
BRAF mutation
Melanoma
binimetinib + encorafenib
Sensitive
:
C2
BRAF mutation
Thyroid Gland Carcinoma
selumetinib
Sensitive
:
C2
BRAF mutation
Melanoma
BVD-523
Sensitive
:
C2
BRAF mutation
Melanoma
trametinib
Sensitive
:
C2
BRAF mutation
Thyroid Gland Papillary Carcinoma
trametinib + dabrafenib
Sensitive
:
C2
BRAF mutation
Thyroid Gland Anaplastic Carcinoma
atezolizumab + cobimetinib
Sensitive
:
C2
BRAF mutation
Colon Cancer
bevacizumab
Sensitive
:
C2
BRAF mutation
Melanoma
selumetinib
Sensitive
:
C2
BRAF mutation
Melanoma
Immunotherapy
Resistant
:
C3
BRAF mutation
Ovarian Cancer
PLX8394
Sensitive
:
C3
BRAF mutation
Melanoma
dabrafenib + KRT-232
Sensitive
:
C3
BRAF mutation
Melanoma
trametinib + dabrafenib + durvalumab
Sensitive
:
C3
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our